Accumulating clinical-and scientific research-based evidence is driving our increased awareness of the significance of the human microbiome (HM) to the healthy and homeostatic operation of the human central nervous system (CNS). HM communities occupy several different but distinct microbial ecosystems on and within the human body, including nasal, oral, and otic cavities, the surface of the skin and the urogenital and the gastrointestinal (GI) tracts. The complex symbiotic inter-relationship between the GI-tract microbiome and its host is strongly influenced by diet and nutrition, and when optimized can be highly beneficial to food digestion, nutrient intake, and immune health (1) (2) (3) (4) (5) (6) . For example, dietary composition ultimately affects the structure, organization, function, and speciation of the HM occupying the GI tract, in part by supplying multiple substrates for microbial metabolism. Typical Western diets containing high fat-cholesterol, low amounts of soluble and insoluble fiber, and sugar-and salt-enrichment not only impart deleterious nutrition but also dietary constraints on the HM. This in turn impacts the supply of microbiome-generated molecules absorbed into the systemic circulation for transport into the extensive neurovasculature of the CNS. This short communication will focus on emerging ideas concerning the contribution of the GI-tract microbiome to human neurological disease with emphasis on Alzheimer's disease (AD) wherever possible.
It is the HM of the GI tract that contains the largest reservoir of microbes in humans, containing about 10 14 microorganisms from at least 1000 distinct microbial species, and outnumbering human somatic cells by about 100 to 1 (1, 7). The total HM has been estimated to encode about 4 × 10 6 genes versus the~26,600 genes of the human host, so again the quantity of HM genes outnumbers host genes in the order of about 150 to 1 (4) . Of the 55 bacterial divisions currently identified, only two are prominent in mammalian GI-tract microbiota, including the anaerobic Bacteroidetes (~48%) and Firmicutes (~51%), with the remaining 1% of phylotypes distributed amongst the Proteobacteria, Verrucomicrobia, Fusobacteria, Cyanobacteria, Actinobacteria, and Spirochetes, with various species of fungi, protozoa, viruses, and other microorganisms making up the remainder (http://www.genome.gov/pages/research/ sequencing/seqproposals/hgmiseq.pdf ). Interestingly, microorganisms making up the smallest proportion of the HM seem to have a disproportionately large effect on host health and disease (see below). Of all GI-tract microbiota, bacterial densities of 10 11 -10 12 /ml are the highest recorded density in any known microbial ecosystem of any living organism (1, 4, (7) (8) (9) (10) . There is currently expanding interest in the ability of these high density GI-tract bacteria to influence host innate-immune, neuromodulatory-, and neurotransmission-functions (3, 4, (11) (12) (13) (14) . Established pathways of GI-CNS communication and mutualism currently include the autonomic nervous system (ANS), the enteric nervous system (ENS), the immune system, and the neuroendocrine system (15) (16) (17) (18) (19) (20) (21) . Remarkably, neuronal signaling pathways along this bidirectional GI-CNS axis remain incompletely understood despite their important roles: (1) in coordinating metabolic-, nutritive-, and homeostatic-functions, and (2) in their functional disruption in chronic diseases such as anxiety, autoimmune-disease, diabetes, metabolic-syndrome, obesity, and stress-induced and progressive neuropsychiatric diseases including AD (3, 11, 12, 20, (22) (23) (24) .
Here we list six specific, highly illustrative examples and recent insights into the interactive nature of the HM with a healthy, homeostatic CNS, and examples of a dysfunctional or altered HM contribution to the development of age-associated neurological disease:
(1) studies of the ENS in germ-free "gnotobiotic" mice, i.e., those missing their microbiome, indicate that commensal GI-tract microbiota are critically essential for membrane electrical characteristics, including ion fluxes, action potentials, and GI-tract sensory neuron excitability, thus providing a potential mechanistic link for the initial exchange of signaling information between the GItract microbiome and the ANS, ENS, CNS neuroimmune-neuroendocrine systems (4, 5, 20, 23, 25) ; (2) as Lactobacillus brevis and Bifidobacterium dentium are capable of metabolizing glutamate to produce gamma-amino butyric acid (GABA), the major inhibitory neurotransmitter in the human CNS (26) . Increased GI-tract GABA appears to correlate with increased CNS GABA levels, but the systemic pathways that contribute to this gut-brain linkage require additional study (3, 26) . In CNS dysfunctions in GABA-mediated neuromodulatory and neurotransmission functions have been linked to the development of anxiety, behavioral deficits, epilepsy, defects in synaptogenesis, depression, and cognitive impairment including AD (16, 17, 23, (27) (28) (29) . Interestingly, epileptic activities including complex partial-seizures and non-convulsive seizures are commonly associated with AD, especially in its early stages, but the contribution of GI-tract microbiome to epileptiform events via GABA modulation is not well understood (30); (3) the secreted, dimeric, 238 amino acid brain-derived neurotrophic factor (BDNF) essential in the maintenance and survival of neurons, has pleiotropic effects on neuronal development, differentiation, synaptogenesis, and the synaptic plasticity that underlies neuronal circuit formation and cognition, and has been found to be decreased in brains and serum from patients with anxiety, behavioral defects, schizophrenia, and AD (27, 31, 32). Interestingly, mice deficient in BDNF have altered development of GI-tract innervations including the vagus nerve, which normally serves as a major constitutive, modulatory communication pathway across the GI-CNS axis (33, 34) . In experimental infection models known to lead to significant alterations in the microbiota profiles, BDNF expression was found to be reduced in the hippocampus and cortex of germ-free "gnotobiotic" mice, and the reduction in the expression of BDNF was found to specifically associate with increased anxiety and progressive cognitive dysfunction (20, 31, 32) ; (4) glutamate is the most abundant excitatory neurotransmitter in the human CNS; the N -methyl-d-aspartate (NMDA) glutamate receptor, a CNSenriched transmembrane sensor that regulates synaptic plasticity and cognition has some intriguing and potentially direct interactions with the HM; for example, the NMDA-, glutamatetargeting, glutathione-depleting, and oxidative-stress-inducing neurotoxin β-N -methylamino-l-alanine (BMAA), found elevated in the brains of patients with amyotrophiclateral sclerosis (ALS), the Parkinsondementia complex of Guam, and AD, has been hypothesized to be generated by Cyanobacteria of the GI-tract microbiome, and anxiety, stress, chronic intestinal inflammatory disease, or malnutrition may further induce BMAA generation to ultimately contribute to neurological dysfunction (13, 35) . Interestingly, BMAA, a neurotoxic amino acid not normally incorporated into the polypeptide chains that constitute brain proteins, has been linked with intra-neuronal protein misfolding, a hallmark feature of the amyloid peptide-enriched senile plaque lesions, and resultant inflammatory neurodegeneration, that characterize AD, ALS, PD, and prion disease (21, 23, 36) . These and other HM-resident Cyanobacteria-generated neurotoxins including saxitoxin and anatoxin-α may further contribute to neurological disease, especially over the course of aging when the intestinal epithelial barrier of the GI tract becomes significantly more permeable (13, 37) ; (5) (12, 40, 41 ). An increased incidence of auto-immunity, exposure to pathogens both pre-and postnatally, and findings of antibodies to brain-specific antigens are common in disorders as diverse as anxiety, autism, depression, obsessivecompulsive disorder, schizophrenia, Parkinson's disease (PD), and AD, together suggesting that differences in exposure and genetic vulnerability toward HM-mediated auto-immunity may be significant determinants of age-related neurological disease course and outcome as humans age (14, 17, 23, 39, (42) (43) (44) (45) (46) ; (6) secretory products of the GI-tract microbiome and translocation of these signaling molecules via the lymphatic and systemic circulation throughout the CNS are just beginning to be identified. Recent advances in metagenomics, RNA sequencing, metatranscriptomics, metaproteomics, and metabolomics continue to clarify our perceptions of the GItract HM and its contribution to health and disease. Just as each individual has a unique"stoichiometrically proportioned" composition of microorganisms in their microbiome, individuals appear to be variably sensitive to agerelated neurological disorders such as AD through the concept of "human biochemical individuality" (11, 16, 47) . Importantly, dietary and GI-tract HM manipulation and the emergence of personalized medicine may be poised to revise and modernize our remedial efforts in the clinical management of brain disorders including AD, and the progressive transformation to more favorable clinical outcomes (30, 48, 49) .
In summary, the human GI tract is a natural habitat for large, diverse, and hostspecific microbial communities including multiple species from the kingdoms of Archaea, Bacteria, the Viruses, and other symbiotic microbiota. How humans coevolved with these complex microbial ecosystems, and how certain microbial species were specifically selected for mutual symbiotic benefit is of extreme interest when assessing critical HM-host interactions involving food digestion, nutrition supply and uptake, metabolic interactions, protection against pathogens and immune system development, maintenance, and dyshomeostasis in both health and disease. To cite another relevant example, abundant evidence suggests that human mitochondria originated from bacteria via endosymbiotic relationships from very early in the evolutionary history of eukaryotes, so cross-reactivity of mitochondria and host immunological responses to selective bacterial GI constituents may have deleterious effects on human mitochondrial function through molecular mimicry (4, 12, 42) . This is evidenced by multiple findings in common autoimmune, inflammationlinked systemic, and neurological disorders including ALS, anxiety, diabetes, epilepsy, metabolic disease, obesity, rheumatic fever, schizophrenia, Sydenham's chorea, PD, AD, and other age-related pathologies, including transgenic animal models for these diseases (2, 4, 12, 23, (44) (45) (46) (50) (51) (52) (53) (54) .
Lastly, since the early investigations of Koch, Metchnikoff, Pasteur, Von Leeuwenhoek, and others on the microbial basis of pathogenicity and disease transmission, Westernized societies have very successfully reduced the incidence of microbial-borne infectious disease, while an environment of autoimmune, cardiovascular, metabolic, and neuroinflammatory diseases continues to flourish. We have only recently begun to truly appreciate the potential for complex and beneficial contributions of the GI-tract HM to host genetics, phenotype, and the development and course of CNS disease. With advancement in nextgeneration, high throughput sequencing and metagenomic technologies our further investigations into the complex microbial ecosystems within us should yield novel HM manipulative strategies for both the optimization of our health and the more effective clinical management of human metabolic, neuropsychiatric, and neurological disorders.
